GI Innovation, Inc.

Quick facts

Phase 3 pipeline

• trastuzumab deruxtecan (T-DXd) · Oncology
  Trastuzumab deruxtecan (T-DXd) is a HER2-targeting antibody-drug conjugate that delivers a DNA crosslinking agent to cancer cells.

Phase 1 pipeline

• GI-101A
• GI-102
• GI-108

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• GI Innovation, Inc. portfolio CI brief
• GI Innovation, Inc. pipeline updates RSS